AGC Biologics A/S: Financial statements 2020
CVR: 25950941
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 1,455,071,000 and a net result of DKK 278,538,000 compared with DKK 154,328,000 the year before. That is an increase of 46.1% compared with the year before. The profit margin was 19.1%. Equity in the 2020 report amounted to DKK 339,677,000. The solvency ratio was 14.5%. The company had 441 employees in the financial year.
- Revenue
- DKK 1,455,071,000
- Gross Profit
- DKK 451,971,000
- Profit/Loss
- DKK 278,538,000
- Equity
- DKK 339,677,000
- Total Assets
- DKK 2,347,541,000
- Employees
- 441
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 1.5B | 452M | 278.5M | 339.7M | 441 |
| 2019 | 996.1M | 257.1M | 154.3M | 215.1M | 377 |
| 2018 | 692.6M | 162.3M | 96.2M | 316.8M | 312 |
| 2017 | 643.6M | 156.8M | 74.5M | 290.6M | 303 |
| 2016 | 521.8M | 116.1M | 68.2M | 216.1M | 245 |
Official annual report
How creditworthy is AGC Biologics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
AGC Biologics A/S has published its annual report for 2019. Revenue came to DKK 996,136,000, and the net result was DKK 154,328,000.
As of March 4, 2020, Patricio Ezequiel Massera has joined the board of directors of AGC Biologics A/S.
About AGC Biologics A/S
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
